IBI3030 / Innovent Biologics - LARVOL DELTA

A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study (EASD 2025) - "IBI3030 demonstrated concurrent improvements in cholesterol homeostasis, glycemic control, and obesity parameters across preclinical models. This novel bioconjugate shows potential for delivering enhanced clinical benefits in cardiovascular disease management."

Preclinical • Metabolic Disorders • Obesity

A Novel Antibody–Peptide Conjugate Targeting PCSK9,GLP-1R,GCGR,GIPR Improves Cardiovascular Risk Markers in Preclinical Study (ADA 2025) - "IBI3030 demonstrated concurrent improvements in cholesterol homeostasis, glycemic control, and obesity parameters across preclinical models. This novel bioconjugate shows potential for delivering enhanced clinical benefits in cardiovascular disease management."

Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions (PRNewswire) - "Innovent Biologics, Inc....announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations."

P3 data • Cardiovascular • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus